Taletrectinib + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer (NSCLC)
Conditions
Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
Aug 21, 2025 → Aug 30, 2033
NCT ID
NCT07154706About Taletrectinib + Placebo
Taletrectinib + Placebo is a phase 3 stage product being developed by Nuvation Bio for Non-small Cell Lung Cancer (NSCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07154706. Target conditions include Non-small Cell Lung Cancer (NSCLC).
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07154706 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non-small Cell Lung Cancer (NSCLC)